Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM
is distinguished from monoclonal gammopathy of undetermined significance by a much …

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among
patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) …

Monoclonal gammopathy of undetermined significance (MGUS) is, in many ways, a unique
hematologic entity. Unlike most hematologic conditions in which the diagnosis is intentional …

T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific
antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved …

Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs
are at high risk of venous thromboembolism (VTE), but data are lacking from large …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …